Virology
Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals

https://doi.org/10.1016/j.diagmicrobio.2018.04.004Get rights and content

Highlights

  • Cure rates with new hepatitis C treatments are high but still vary based on genetics.

  • Cure rates are lower in patients with ∆G/∆G for the interferon lambda 4 gene.

  • The negative impact of ∆G/∆G genotype may pertain more to blacks and Hispanics.

Abstract

In direct acting antiviral (DAA)-treated HCV genotype 1, the sustained virologic response rate with the ∆G/∆G genotype of IFNL4 rs368234815 (86.8%) was significantly lower than with ∆G/TT (95.9%, P = 0.03) or TT/TT (98.6%, P = 0.01). The SVR odds ratio for ∆G/∆G compared to TT/TT was 0.10 (P = 0.03). IFNL4 genotype might predict DAA-response.

Section snippets

Acknowledgements/COI

Funding: This work was supported by intramural funds from the Department of Veterans Affairs and the Intramural Research Program of the National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict/Competing Interest Statement: None of the authors report any conflict of interest with the work presented in this manuscript.

View full text